1026666-01-2

Upstream product

• 1026666-00-1 Methyl 5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-(3-methanesulfonyl-aminopropyl)-1H-pyrrole-2-carboxylate 

Downstream Products

• 1243243-26-6 1'-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-(3-methanesulfonylamino-propyl)-1H-pyrrole-2-carbonyl]-4,4-dimethyl[1,4']bipiperidinyl-4'-carboxamide 
• 1243243-27-7 1'-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-(3-methanesulfonylamino-propyl)-1H-pyrrole-2-carbonyl]-4,4-difluoro[1,4']bipiperidinyl-4'-carboxamide 
• 1026665-95-1 1'-{[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-{3-[(methylsulfonyl)amino]-propyl}-1H-pyrrol-2-yl]carbonyl}-1,4'-bipiperidine-4'-carboxamide 

Relevant academic research and scientific papers

Rational design of a novel peripherally-restricted, orally active CB 1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif

A new series of 2,3-diarylpyrroles have been prepared and evaluated as CB1 antagonists. Modulation of the topological polar surface area allowed the identification of high affinity peripherally-restricted CB 1 antagonists. Compound 1

PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to compounds having the formula (I): Wherein R1, R2, R3, R4, R5, R6, R7 and R9 and A-R9 are as defined herein. Also disclosed are the